Precision Medicine in Oncology®

Lead author, Alice T. Shaw, MD, PhD, from the Massachusetts General Hospital, reviews the first published results from a randomized phase III trial investigating crizotinib in patients with ALK-positive non-small cell lung cancer.

Albert S. Baldwin, Jr, PhD, focuses on understanding the regulation and biological functions of NF-κB and its role in disease, particularly in cancer, in a laboratory he heads at the UNC Lineberger Comprehensive Cancer Center.

Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, highlights information presented at the 2013 American Society of Clinical Oncology (ASCO) Meeting.

Researchers at the National Cancer Institute have developed a comprehensive analysis of coding variants in nine of the most frequently studied human tumor cell lines in cancer research.

The FDA has approved afatinib, along with a companion diagnostic, to treat patients with metastatic non-small cell lung cancer who express specific types of EGFR mutations.

Josep Tabernero, MD, PhD, from the Vall d'Hebron University Hospital, believes that in order to treat patients with gastrointestinal cancers more effectively, researchers must focus on the molecular classification of particular subpopulations.

Highlights of key findings from several phase I clinical trials that provide insight into new and emerging druggable targets and targeted therapies.

Cancer centers are beginning to establish oncology nurse navigator programs with integrated processes for assessment, identification, referral, education, care, and support for patients whose gynecologic cancers may be genetically-based.

Women with breast cancer who are carriers of BRCA1 mutations have increased mortality compared with noncarriers, according to a retrospective study carried out in the Netherlands.

Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, discusses the potential predictive impact of KRAS and NRAS mutations in metastatic colorectal cancer.

The translation of scientific advances in nanotechnology into cancer therapies, in vitro assays, and imaging tools is poised for takeoff, amid fresh excitement among investors and a mushrooming of findings from leading research institutions.

A dual-action PARP inhibitor has shown sufficient clinical activity to continue its investigation in women with recurrent BRCA-mutant ovarian cancer.

The complex regulation of NF-κB activation has presented significant challenges for the development of anticancer agents, but researchers are now beginning to better understand and embrace this complexity to drive development of a variety of novel NF-κB-targeting strategies.